Regeneron Earnings Preview: Dupixent Is Booming, But It's Still Overvalued

Regeneron is rated Sell at $808, with estimated fair value of approximately $675, implying 16.4% downside. Strong Dupixent growth is tempered by EYLEA HD gains being offset by declines in legacy products, while Dupixent’s 2031 patent expiration and biosimilar risks constrain long-term upside. Slowing overall franchise erosion is identified as critical to future cash-flow projections.

Analysis

The key valuation risk is a timing mismatch: near-term cash flow depends on whether EYLEA HD adoption can offset legacy EYLEA erosion, while part of the long-run growth case is exposed to post-2031 competition. If legacy erosion accelerates before HD uptake is demonstrated in reported results, investors may lower near-term cash-flow estimates and assign less value to growth beyond the exclusivity window at the same time. Conversely, sustained Dupixent growth could support earnings but does not by itself resolve the ophthalmology transition or the eventual loss-of-exclusivity risk.

The cited fair value is an analyst estimate, not an independently verified floor; treat the implied discount as a thesis to test, not a catalyst. In the next 1–3 months, the relevant catalysts are quarterly product-level sales, management commentary on EYLEA HD conversion, and any change to guidance. Over 6–18 months, repeated evidence that HD growth is outpacing legacy erosion would weaken the bearish case. A longer-term risk is that competition after 2031 arrives earlier or proves more disruptive than current assumptions, though the article supplies no timing or market-share data to quantify that risk.

Key Decisions for Investors

• Keep REGN underweight versus a neutral biotech exposure; avoid treating the analyst fair-value estimate as a precise downside target. The near-term thesis is product-transition execution, not an imminent patent event.
• For an existing long, use the next earnings report as a checkpoint: track EYLEA HD growth alongside legacy EYLEA sales and total franchise trends. If the franchise stabilizes and guidance holds, reduce or exit the underweight; if erosion worsens without offsetting HD gains, maintain it.
• Do not add an outright short solely on the stated valuation gap. Consider a relative-value short only if product-level results show persistent erosion and the stock fails to reflect weaker guidance; otherwise timing and strong Dupixent performance could squeeze the position.
• Verify product-level sales, EYLEA HD adoption, guidance changes, and the assumptions behind the 2031 competition scenario. The bearish thesis is falsified near term by sustained franchise stabilization and stronger-than-expected HD offset; it is reinforced by accelerating erosion or a material downward guidance revision.